Page last updated: 2024-09-04

cyc 202 and Lymphoma, Mantle-Cell

cyc 202 has been researched along with Lymphoma, Mantle-Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bertoni, F; Catapano, C; Cavalli, F; Gianella-Borradori, A; Lacrima, K; Lambertini, C; Maccallum, DE; Rinaldi, A; Taborelli, M; Valentini, A; Zucca, E	1

Other Studies

1 other study(ies) available for cyc 202 and Lymphoma, Mantle-Cell

Article	Year
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinases; Humans; In Situ Nick-End Labeling; Lymphoma, Mantle-Cell; Purines; Roscovitine; Transcription Factors	2005

Article

Year

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinases; Humans; In Situ Nick-End Labeling; Lymphoma, Mantle-Cell; Purines; Roscovitine; Transcription Factors

2005